文献速递腹部技术与安全CT

CT结肠成像与多靶点粪便DNA检测用于结直肠癌筛查的成本效果分析

CT Colonography versus Multitarget Stool DNA Test for Colorectal Cancer Screening: A Cost-Effectiveness Analysis.
PubMed 文献 · Radiology · 2025-01-01

本研究构建状态转换马尔可夫模型,模拟1万名45岁美国人群,比较每3年多靶点粪便DNA检测、每5年CT结肠成像(CTC)对≥6mm息肉即刻切除、以及CTC对6-9mm息肉3年随访并对≥10mm息肉转诊结肠镜三种筛查策略。CTC两种策略均较mt-sDNA及不筛查更具成本效果且节省费用,其中CTC随访策略成本效果最佳。

要点

  • CTCconv策略较不筛查降低结直肠癌累积发病率75%,CTCsurv策略降低70%,mt-sDNA降低59%。
  • mt-sDNA每获得一个质量调整生命年需8878美元,而两种CTC策略均节省费用。
  • CTCsurv策略(小息肉3年随访、大息肉转诊结肠镜)成本与临床效果总体平衡最佳。

核心结论

  • 两种CTC筛查策略均优于mt-sDNA筛查和不筛查,节省费用并提高临床效果;对小息肉行3年随访、对大息肉转诊结肠镜的CTC策略成本与临床效果总体平衡最佳。

研究设计与样本

  • 采用状态转换马尔可夫模型,基于更新的大肠息肉自然史证据,模拟代表45岁美国人群的10000人假设队列,并进行了多层面模型验证和详细敏感性分析。

诊断标准与关键数值

  • 不筛查时结直肠癌累积发病率为7.5%(n=752);mt-sDNA筛查降低59%(n=310),CTCconv降低75%(n=190),CTCsurv降低70%(n=223)。
  • 不筛查、mt-sDNA、CTCconv、CTCsurv的人均项目成本分别为4955美元、6011美元、4422美元、3913美元。
  • mt-sDNA每获得一个质量调整生命年的成本为8878美元,两种CTC策略均产生费用节省。
  • CTC策略优于mt-sDNA和不筛查(即临床效果更好且更具成本效果[费用节省]);但CTCconv策略成本效果不如CTCsurv策略,因更多光学结肠镜检查相关费用未能抵消相应质量调整生命年的小幅增益。
  • 当结直肠癌筛查从50岁和65岁开始时,结果相似。

临床应用与阅片要点

  • 在结直肠癌筛查方案比较中,CTC策略(尤其CTCsurv)在成本和临床效果上均优于mt-sDNA筛查及不筛查。
  • CTCsurv策略为6-9mm小息肉行3年CTC随访、≥10mm大息肉转诊结肠镜,成本效果总体平衡最佳。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Background Colorectal cancer (CRC) is largely preventable or curable with effective screening. Purpose To compare both the clinical efficacy and cost effectiveness of CRC screening with CT colonography (CTC) with those of multitarget stool DNA (mt-sDNA) testing. Materials and Methods A state-transition Markov model was constructed using updated natural history evidence for colorectal polyps applied to a hypothetical 10 000-person cohort representative of the 45-year-old U.S. population. Three screening strategies were modeled with these data: mt-sDNA testing every 3 years, the conventional CTC (CTCconv) strategy of immediate polypectomy for all polyps measuring at least 6 mm every 5 years, and the surveillance CTC (CTCsurv) strategy of 3-year CTC follow-up for small polyps (6-9 mm) and polypectomy for large polyps (≥10 mm). Multifaceted model validation was performed to confirm robustness. A detailed sensitivity analysis was performed in addition to the base-case scenario. Results Without screening, the cumulative incidence of CRC was 7.5% (n = 752), which was reduced by 59% (n = 310) with mt-sDNA, 75% (n = 190) with CTCconv, and 70% (n = 223) with CTCsurv screening. The estimated programmatic costs per person for no screening, mt-sDNA, CTCconv, and CTCsurv were $4955, $6011, $4422, and $3913, respectively. The estimated cost per quality-adjusted life year (QALY) gained for mt-sDNA testing was $8878, whereas both CTC strategies resulted in cost savings. Accordingly, CTC strategies dominated over both mt-sDNA and no screening (ie, more clinically efficacious and more cost-effective [cost-saving]). However, the CTCconv strategy was not as cost-effective as the CTCsurv strategy, as costs related to more optical colonoscopies did not offset the corresponding small gains in QALYs. The results were similar when CRC screening began at 50 and 65 years of age. Conclusion Both CTC screening strategies dominated over mt-sDNA screening and no screening, yielding cost savings and increased clinical efficacy. The CTC strategy consisting of 3-year surveillance for small colorectal polyps and colonoscopy referral for large polyps achieved the best overall balance of cost and clinical efficacy. © RSNA, 2025 Supplemental material is available for this article. See also the editorial by Galgano and Smith in this issue.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Pickhardt PJ, Correale L, Hassan C, et al. CT Colonography versus Multitarget Stool DNA Test for Colorectal Cancer Screening: A Cost-Effectiveness Analysis. Radiology. 2025. PMID: 40492916. doi:10.1148/radiol.243775

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。